- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05572970
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.
Study Overview
Detailed Description
This study will not exceed 100 participants. Participants will be reevaluated annually to assess the treatment benefit of zalifrelimab and/or balstilimab and thereby, continued eligibility for treatment. Under this program, treatment will be continued with balstilimab, as either monotherapy or as used in combination therapy with zalifrelimab, for participants that have previously received one or both of these investigational medicinal products in a clinical study.
Study Type
Expanded Access Type
- Individual Patients
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- Available
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, United States, 85711
- Available
- Arizona Oncology Associates
-
-
California
-
Newport Beach, California, United States, 92663
- Available
- Hoag Gynecologic Oncology
-
San Francisco, California, United States, 94158
- Available
- University of California, San Francisco Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43212
- Available
- The Ohio State University Wexner Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Available
- Women & Infants Hospital of Rhode Island
-
-
Texas
-
Flower Mound, Texas, United States, 75028
- Available
- Texas Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Agenus Inc.
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-750-EAP-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.